SOFIDROX CAPSULE 500mg

Product Information

Registration Status: Active

SOFIDROX CAPSULE 500mg is approved to be sold in Singapore with effective from 2001-09-13. It is marketed by APEX PHARMA MARKETING PTE LTD, with the registration number of SIN11665P.

This product contains Cefadroxil 500mg in the form of CAPSULE. It is approved for ORAL use.

This product is manufactured by XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD in MALAYSIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Cefadroxil

Description

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

Indication

For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes

Mechanism of Action

Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor.

Pharmacokinetics

Absorption
Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption.
Distribution
Metabolism
Elimination

Toxicity

Nausea, vomiting, diarrhoea, allergic rashes may occur

Active Ingredient/Synonyms

CDX | Cefadroxil anhydrous | Cefadroxilo | Cefadroxilum | Cephadroxil | D-Cefadroxil | Cefadroxil |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank